谢锦伟;蔡迎春;马俊;康鹏德;沈彬;杨静;周宗科;裴福兴;

• 1:四川大学华西医院骨科

摘要(Abstract)：

[目的]单中心大样本连续病例观察性研究旨在探讨初次全髋关节置换术中使用氨甲环酸对术后静脉血栓栓塞症的影响及THA围手术期抗纤溶与抗凝平衡的初步临床疗效。[方法]基于国家卫生行业数据库平台,前瞻性收集本中心行初次单侧全髋关节置换术患者的基本资料,纳入患者围手术期静脉或静脉联合局部使用氨甲环酸抗纤溶,术后6 h开始序贯使用低分子肝素或利伐沙班抗凝。主要观察指标为血栓发生情况及术后30 d全因死亡人数;次要指标为输血率;同时根据氨甲环酸使用方式进行亚组分析。[结果]2012~2014年,共纳入本中心初次单侧全髋关节置换术患者3 043例。共有199例(6.54%)发生术后血栓栓塞事件,其中肌间静脉血栓183例(6.01%),非症状性深静脉血栓16例(0.53%),无发生症状性深静脉血栓、肺栓塞及死亡患者;186例(6.1%)患者接受输血。亚组分析结果提示静脉联合局部使用氨甲环酸较单纯静脉使用术后输血率更低(5.4%Vs 7.2%),差异有统计学意义(P=0.039);深静脉血栓的发生率并没有增加(0.6%Vs 0.4%,P=0.578)。[结论]THA围手术期使用TXA抗纤溶后,序贯抗凝维持两者平衡,可安全的减少围手术期输血率。

关键词(KeyWords)： 全髋关节置换术;静脉血栓栓塞症;抗纤溶;抗凝

Abstract:

Keywords:

基金项目(Foundation): 卫生部2013年度卫生行业科研专项项目(编号:201302007)

作者(Author): 谢锦伟;蔡迎春;马俊;康鹏德;沈彬;杨静;周宗科;裴福兴;

Email:

DOI:

参考文献(References)：

• [1]Alshryda S,Mason J,Sarda P,et al.Topical(intra-articular)tranexamic acid reduces blood loss and transfusion rates following total hip replacement:a randomized controlled trial(TRANX-H)[J].J Bone Joint Surg Am,2013,95(21):1969-1974.
• [2]Vamvakas EC,Blajchman MA.Transfusion related mortality:the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention[J].Blood,2009,113(15):3406-3417.
• [3]Newman ET,Watters TS,Lewis JS,et al.Impact of perioperative allogeneic and autologous blood transfusion on acute wound infection following total knee and total hip arthroplasty[J].J Bone Joint Surg Am,2014,96(4):279-284.
• [4]Kambayashi J,Sakon M,Yokota M,et al.Activation of coagulation and fibrinolysis during surgery,analyzed by molecular markers[J].Thromb Res,1990,60(1):157-167.
• [5]岳辰,康鹏德,沈彬,等.氨甲环酸用于首次髋关节置换术的系统评价和Meta分析[J].中国矫形外科杂志,2014,21(12):1167-1172.
• [6]谢锦伟,岳辰,裴福兴.氨甲环酸在全髋关节置换术中的有效性与安全性研究进展[J].中国矫形外科杂志,2014,22(20):1856
• [7]Lange M,Van Aken H,Westphal M.Prevention and treatment of major blood loss[J].N Engl J Med,2007,357(12):1260.
• [8]孙程,陆海明,吕杰,等.氨甲环酸在初次全髋关节置换术中的应用[J].中国矫形外科杂志,2015,23(2):139-143.
• [9]Zhou XD,Tao LJ,Li J,et al.Do we really need tranexamic acid in total hip arthroplasty?A meta-analysis of nineteen randomized controlled trials[J].Arch Orthop Trauma Surg,2013,133(7):1017-1027.
• [10]Duncan CM,Gillette BP,Jacob AK,et al.Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty[J].J Arthroplasty,2015,30(2):272-276.
• [11]Poeran J,Rasul R,Suzuki S,et al.Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the united states:retrospective analysis of effectiveness and safety[J].BMJ,2014,349:4829.
• [12]邱贵兴,杨庆铭,余楠生,等.低分子肝素预防髋、膝关节手术后下肢深静脉血栓形成的多中心研究[J].中华骨科杂志,2006,26(12):819-822.
• [13]王峰,姚晨,史冬泉,等.全髋关节置换术后深静脉血栓发生的随机对照研究[J].中华骨科杂志,2010,30(4):381-385.
• [14]姚尧,张成绩,戴小宇,等.关节置换术后下肢深静脉血栓形成的解剖分布[J].中华骨科杂志,2013,33(9):912-916.
• [15]Galanaud JP,Sevestre MA,Genty C,et al.OPTIMEV SFMV investigators.Comparison of the clinical history of symptomatic isolated muscular calf vein thrombosis versus deep calf vein thrombosis[J].J Vasc Surg,2010,52(4):932-938.
• [16]Huang Z,Ma J,Pei F,et al.Combination of intravenous and topical application of tranexamic acid in primary total knee arthroplasty:a prospective randomized controlled trial[J].J Arthroplasty,2014,29(12):2342-2346.
• [17]Sharrock NE,Go G,Sculco TP,et al.Changes in circulatory indices of thrombosis and fibrinolysis during total knee arthroplasty performed under tourniquet[J].J Arthroplasty,1995,10(4):523-528.
• [18]Lieberman JR,Pensak MJ.Prevention of venous thromboembolic disease after total hip and knee arthroplasty[J].J Bone Joint Surg Am,2013,95(19):1801-1811.